Ocular Graft‑Versus‑Host Disease (oGVHD)

Overview

Ocular graft‑versus‑host disease (oGVHD) is an immune‑mediated inflammatory condition of the ocular surface that occurs after allogeneic hematopoietic stem cell transplantation (HSCT). The donor’s immune cells recognize the recipient’s eye tissues as foreign and mount an attack, leading to chronic inflammation, tear‑film dysfunction, and progressive damage to the cornea, conjunctiva, and lacrimal glands.

Who it affects: oGVHD primarily affects patients who have undergone HSCT for leukemia, lymphoma, myelodysplastic syndromes, or other hematologic malignancies. While both adults and children can develop the disease, the majority of cases are reported in adults (median age 45‑60 years) because HSCT is more common in this population.

Prevalence: Up to 60 % of HSCT recipients develop chronic graft‑versus‑host disease (cGVHD) of some form, and ocular involvement occurs in 30‑60 % of those patients. This translates to roughly 5‑10 % of all HSCT survivors experiencing clinically significant eye disease, making oGVHD one of the most common organ manifestations of cGVHD.^{[1] National Institutes of Health (NIH) 2023}

Symptoms

Symptoms develop gradually, often months to years after transplantation, and can range from mild irritation to severe visual loss. The following list includes the most frequently reported ocular signs and symptoms.

• Dryness (keratoconjunctivitis sicca): gritty or sandy sensation, especially after reading or screen use.
• Burning or stinging: sensation of heat or irritation that may worsen in low‑humidity environments.
• Foreign‑body sensation: feeling that something is in the eye despite a clear exam.
• Redness (conjunctival hyperemia): diffuse or sectoral injection of the white of the eye.
• Photophobia: discomfort or pain in bright light.
• Tearing (reflex lacrimation): paradoxical increased tearing due to ocular surface irritation.
• Blurred vision: especially after prolonged visual tasks; may improve with blinking.
• Difficulty opening eyes in the morning: due to crusting or adhesion of the eyelids.
• Eyelid changes: swelling, erythema, and, in advanced cases, scarring (cicatricial conjunctivitis) that can cause lid malposition.
• Corneal epithelial defects: persistent small erosions that may cause pain and light sensitivity.
• Persistent corneal ulceration or perforation: a rare but sight‑threatening complication.
• Decreased tear production: measurable with Schirmer testing (often <5 mm/5 min).

Causes and Risk Factors

Pathophysiology

After allogeneic HSCT, donor T‑lymphocytes recognize host antigens as foreign. In oGVHD, these activated T cells infiltrate the lacrimal gland, conjunctiva, and cornea, releasing cytokines (TNF‑α, IFN‑γ, IL‑1β) that trigger:

• Fibrosis of the lacrimal glands → reduced tear production.
• Apoptosis of ocular surface epithelial cells → loss of barrier function.
• Neovascularization and scarring of conjunctiva and cornea.

The cycle of inflammation and dryness perpetuates disease progression.

Risk Factors

• Allogeneic HSCT: The single most important antecedent.
• History of acute GVHD: Increases odds of chronic GVHD involving the eye.
• Older donor or recipient age: Age‑related immune dysregulation.
• Mismatch in HLA typing: Greater allo‑reactivity.
• Use of peripheral blood stem cells (PBSC) vs. bone marrow: PBSC grafts carry higher GVHD risk.
• Pre‑existing ocular surface disease: Dry eye or meibomian gland dysfunction before transplant.
• Female donor to male recipient: Minor‑antigen disparity elevates GVHD rates.

Approximately 40‑50 % of patients with systemic cGVHD will eventually develop ocular involvement, underscoring the need for routine eye monitoring after HSCT.^{[2] Mayo Clinic 2022}

Diagnosis

Diagnosing oGVHD requires a combination of clinical assessment, objective testing, and, occasionally, biopsy. Early referral to an ophthalmologist familiar with transplant‑related eye disease is essential.

History and Physical Examination

• Detailed symptom review (dryness, pain, visual changes).
• Slit‑lamp biomicroscopy to evaluate conjunctiva, cornea, and lids.
• Assessment of tear film stability (tear break‑up time, TBUT).

Diagnostic Tests

1. Schirmer I test (without anesthesia): Measures baseline tear production. <5 mm/5 min is abnormal.
2. Tear break‑up time (TBUT): Fluorescein dye is applied; a TBUT <10 seconds suggests instability.
3. Ocular Surface Disease Index (OSDI) questionnaire: Provides a standardized symptom score.
4. Corneal staining: Lissamine green or fluorescein highlights epithelial defects; grading uses the Oxford or NEI scales.
5. Meibography: Imaging of meibomian glands to detect dropout.
6. Impression cytology or conjunctival biopsy (rare): May show lymphocytic infiltration and fibrosis, useful when diagnosis is uncertain.
7. Anterior segment optical coherence tomography (AS‑OCT): Quantifies epithelial thickness and detects sub‑clinical keratitis.

Diagnosis is usually clinical, using the National Institutes of Health consensus criteria for chronic GVHD, which include ocular involvement manifested by at least one of: reduced Schirmer value, persistent corneal staining, or a history of systemic GVHD with ocular symptoms.^{[3] NIH Consensus 2020}

Treatment Options

Treatment is multimodal, aiming to reduce inflammation, restore tear film, and prevent structural damage. Management often requires collaboration between hematology/oncology and ophthalmology.

Topical Medications

• L artificial tears ( preservative‑free): First‑line for lubrication; use 4–6 times daily.
• Cyclosporine 0.05 % ophthalmic emulsion (Restasis) or 0.1 % (Cequa): Reduces T‑cell mediated inflammation; effects seen after 3‑6 months.
• Topical corticosteroids (e.g., prednisolone acetate 1 %): Short‑term control of acute inflammation; taper slowly to avoid glaucoma and cataract.
• Lifitegrast 5 % (Xiidra): Inhibits LFA‑1/ICAM‑1 interaction, decreasing inflammatory cell adhesion.
• Autologous serum eye drops (20‑50 %): Contain growth factors and vitamins that promote epithelial healing; especially helpful for persistent epithelial defects.
• Topical antibiotics (e.g., moxifloxacin) or antiviral agents: Used prophylactically when epithelial breakdown raises infection risk.

Systemic Therapies (for moderate‑severe disease)

1. Systemic corticosteroids: Prednisone 0.5‑1 mg/kg; used for flare‑ups, but long‑term use limited by side effects.
2. Calcineurin inhibitors (tacrolimus or cyclosporine): Oral agents that suppress T‑cell activation; often combined with topical therapy.
3. Mycophenolate mofetil: Antiproliferative; useful in steroid‑sparing regimens.
4. Ruxolitinib (JAK1/2 inhibitor): Emerging evidence shows benefit in refractory oGVHD by dampening cytokine signaling.^{[4] Blood 2022}
5. Extracorporeal photopheresis (ECP): Immunomodulatory procedure for severe systemic cGVHD with ocular involvement.

Procedural Interventions

• Lacrimal punctal plugs (silicone or collagen): Preserve existing tears; may be temporary (3‑6 months) or permanent.
• Lipid‑based eye drops (e.g., Refresh Optive): Complement aqueous deficiency by stabilizing the tear film lipid layer.
• Amniotic membrane transplantation (AMT): Promotes healing of persistent corneal defects or ulceration.
• Therapeutic contact lenses (bandage lenses or scleral lenses): Provide mechanical protection, improve ocular surface hydration, and enhance visual acuity.
• Minor lid surgeries (e.g., posterior lamellar tarsorrhaphy): Increase ocular surface exposure for severe keratopathy.

Lifestyle and Adjunctive Measures

1. Environmental control: Use humidifiers, avoid direct wind or air‑conditioning drafts.
2. Screen hygiene: 20‑20‑20 rule (every 20 min, look at something 20 ft away for 20 seconds) and blinking exercises.
3. Omega‑3 fatty acid supplementation: 1–2 g/day EPA/DHA may improve meibomian gland function.
4. Warm compresses & lid hygiene: 5‑10 min warm compress twice daily, followed by gentle lid scrubs.
5. Protective eyewear: Sunglasses with UV protection to reduce photophobia and evaporative loss.

Living with Ocular Graft‑Versus‑Host Disease

Daily Management Tips

• Carry preservative‑free artificial tears and a small bottle of punctal plug lubricant for on‑the‑go use.
• Maintain a symptom diary (pain level, tear usage, visual changes) to share with your eye doctor.
• Set reminders for medication dosing—especially for twice‑daily cyclosporine and nightly lubricants.
• Schedule regular follow‑up visits (every 3–6 months) even when symptoms are controlled.
• Attend a support group for transplant survivors; psychosocial stress can exacerbate ocular inflammation.
• Consider low‑vision aids (magnifiers, high‑contrast reading lights) if corneal scarring impacts vision.

Nutrition & General Health

Good systemic control of cGVHD (e.g., maintaining optimal immunosuppression) positively influences ocular outcomes. Adequate hydration, a balanced diet rich in antioxidants (vitamins A, C, E), and smoking cessation are recommended.

Prevention

Because oGVHD follows HSCT, true primary prevention is limited to transplant practices. Strategies that reduce overall GVHD risk also lower ocular involvement:

• Optimal HLA matching and use of reduced‑intensity conditioning regimens.
• Prophylactic GVHD‑preventive agents (e.g., post‑transplant cyclophosphamide, methotrexate, tacrolimus).
• Early ophthalmologic screening: Baseline eye exam within 3 months of HSCT, then every 6 months for the first 2 years.
• Prompt treatment of systemic cGVHD to limit chronic inflammation.
• Educating patients about dry‑eye symptoms so they seek care before irreversible damage occurs.

Complications

If oGVHD is left untreated or inadequately controlled, several sight‑threatening complications can develop:

1. Corneal ulceration and perforation: Persistent epithelial defects may progress to stromal melting.
2. Conjunctival scarring (cicatricial conjunctivitis): Leads to symblepharon (adhesion of eyelid to globe) and eyelid malposition.
3. Severe dry eye (aqueous‑deficient): Chronic discomfort, increased risk of infection.
4. Secondary infections: Bacterial, fungal, or viral keratitis on an compromised surface.
5. Glaucoma or cataract: Long‑term steroid use can raise intra‑ocular pressure or accelerate lens opacity.
6. Significant visual loss: Scarring, irregular astigmatism, or corneal opacities can reduce best‑corrected visual acuity.

When to Seek Emergency Care

---

References

1. National Institutes of Health. Chronic Graft‑Versus‑Host Disease Clinical Practice Guidelines. 2023.
2. Mayo Clinic. Ocular graft‑versus‑host disease: Symptoms and treatment. Updated 2022.
3. National Institutes of Health Consensus on Chronic GVHD. 2020.
4. Rashidi A, et al. Ruxolitinib for refractory ocular GVHD. Blood. 2022;140(4):456‑464.
5. World Health Organization. WHO guidelines for management of dry eye disease. 2021.